An Estimate of Protective Immunity against SARS-CoV2: Comparison of Different Vaccine Types
DOI:
https://doi.org/10.53560/PPASB(60-3)749Keywords:
SARS-COV2, Vaccine Effectiveness, COVID-19 Vaccine Types, Ct ValueAbstract
Several types of vaccines have been approved to prevent SARS-CoV-2 infection. Few studies are conducted on the efficacy of COVID-19 vaccines. Vaccination is important to eliminate and fight SARS-CoV-2 infection and several vaccines have been approved. This study aimed to assess the incidence density of COVID-19 infection among the community, estimate the effectiveness of different types of vaccines (inactivated virus, viral vector or mRNA) and efficiency of incomplete and complete vaccination. In this observational cross-sectional study, a total of 4924 specimens were received from 1st January 2022 to 2nd February 2022 for the detection of SARS-CoV-2. The patient’s age, gender, and vaccination data were recorded and S, N, and ORF 1ab genes were amplified after RNA extraction through PCR. out of which 1034 (20.99%) cases were positive. Among 1034 (20.99%) positive cases, 418 and 616 patients were vaccinated and non-vaccinated respectively. The cases of SARS-CoV-2 in vaccinated patients were categorized into a sudden infection (≤ 10 days) and late infection (≥10 days) after the incomplete and complete dose of vaccination. Vaccination provides partial protection against SARS-CoV-2 infection. This might be due to the low efficacy and inability to detect recent variations in the protein structure of the virus.
References
K. Dooling, M. Marin, M. Wallace, N. McClung, M. Chamberland, G.M. Lee, H.K. Talbot, J.R. Romero, B.P. Bell, and S.E. Oliver. The Advisory Committee on Immunization Practices updated interim recommendation for allocation of COVID-19 vaccine-United States, December 2020. Morbidity and Mortality Weekly Report (MMWR) 69:1657-1660 (2021).
J.S. Tregoning, E.S. Brown, H.M. Cheeseman, K.E. Flight, S.L. Higham, N.M. Lemm, B.F. Pierce, D.C. Stirling, Z. Wang, and K.M. Pollock. Vaccines for COVID-19. Clinical and Experimental Immunology 202(2): 162-192 (2020).
A. Callegaro, D. Borleri, C. Farina, G. Napolitano, D. Valenti, M. Rizzi, and F. Maggiolo. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS Cov-2 infection. Journal of Medical Virology 93: 4612-4615 (2021).
S. Malhotra, K. Mani, R. Lodha, S. Bakhshi, V.P. Mathur, P. Gupta, S. Kedia, J. Sankar, P. Kumar, A. Kumar, V. Ahuja, S. Sinha, R. Guleria, A. Dua, S. Ahmad, R. Sathiyamoorthy, A. Sharma, T. Sakya, V. Gaur, S. Chaudhary, S. Sharma, D. Madan, A. Gupta, S. Virmani, A. Gupta, N. Yadav, S. Sachdeva, S. Sharma, S. Singh, A. Pandey, M. Singh, D. Jhurani, S. Sarkar, A.K. Lokade, A. Mohammad, S. Pandit, R. Dubey, A.K. Singh, N. Gohar, D. Soni, A. Bhattacharyya, S. Rai, S. Tummala, I. Gupta, and S. Shukla. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. JAMA network 5(1): e2142210 (2022).
F.C. Zhu, X.H. Guan, Y.H. Li, J.Y. Huang, T. Jiang, L.H. Hou, J.X. Li, B.F. Yang, L. Wang, W.J. Wang, S.P. Wu, Z. Wang, X.H. Wu, J.J. Xu, Z. Zhang, S.Y. Jia, B.S. Wang, Y. Hu, J.J. Liu, J. Zhang, X.A. Qian, Q. Li, H.Y. Pan, H.D Jiang, P. Deng, J.B. Gou, X.W. Wang, X.H. Wang, and W. Chen. Immunogenicity and safety of a recombinant of adeno virus type five vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet 396: 479-488 (2020).
O. Sharma, A.A. Sultan, H. Ding, and C.R. Triggle. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in immunology 11: 585354 (2020).
K.E. Stephenson, M.L. Gars, J. Sadoff, A.M. de-Groot, D. Heerwegh, C. Truyers, C. Atyeo, C. Loos, A. Chandrashekar, K. McMahan, L.H. Tostanoski, J. Yu, M.S. Gebre, C. Jacob-Dolan, Z. Li, S. Patel, L. Peter, J. Liu, E.N. Borducchi, J.P. Nkolola, M. Souza, C.S. Tan, R. Zash, B. Julg, R.R. Nathavitharana, R.L. Shapiro, A.A. Azim, C.D. Alonso, K. Jaegle, J.L. Ansel, D.G. Kanjilal, C.J. Guiney, C. Bradshaw, A. Tyler, T. Makoni, K.E. Yanosick, M.S. Seaman, D.A. Lauffenburger, G. Alter, F. Struyf, M. Douoguih, J.V. Hoof, H. Schuitemaker, and D.H. Barouch. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. Journal of the American Medical Association (JAMA) 325:1535-1544 (2021).
A.M. Cavanaugh, K.B. Spicer, D. Thoroughman, C. Glick, and K. Winter. Reduced risk of reinfection with SARS-CoV-2 After COVID-19 vaccination - Kentucky, May-June 2021. Morbidity and Mortality Weekly Report (MMWR) 70(32):1081-1083 (2021).
J.L. Bernal, N. Andrews, C. Gower, E. Gallagher, R. Simmons, S. Thelwall, J. Stowe, E. Tessier, N. Groves, G. Dabrera, R. Myers, C.N.J. Campbell, G. Amirthalingam, M. Edmunds, M. Zambon, K.E. Brown, S. Hopkins, M. Chand, and M. Ramsay. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. The New England Journal of Medicine 385(7): 585-594 (2021).
D. Desai, A.R. Khan, M. Soneja, A. Mittal, S. Naik, P. Kodan, A. Mandal, G.T. Maher, R. Kumar, A. Agarwal, N.R. Gowda, H. Vikas, P. Kumar, S. Pandey, R.M. Pandey, A. Kumar, A. Ray, P. Jorwal, N. Nischal, A. Choudhary, M. Brijwal, K. Madan, R. Lodha, S. Sinha, L. Dar, N. Wig, and R. Guleria. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. Lancet. Infectious diseases 22(3): 349-356 (2022).
S. Shah, T. Singhal, N. Davar, and P. Thakkar. No correlation between Ct values and severity of disease or mortality in patients with COVID 19 disease. Indian Journal of Medical Microbiology 39(1): 116-117 (2021).
